paroxetine	9-hydroxyrisperidone	4	6	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		32937	none	D017374	none
paroxetine	9-hydroxyrisperidone	4	6	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		32937	none	D017374	none
paroxetine	9-hydroxyrisperidone	5	6	true	positive	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		32937	none	D017374	none
paroxetine	9-hydroxyrisperidone	5	6	true	positive	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		32937	none	D017374	none
paroxetine	9-hydroxyrisperidone	6	6	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		32937	none	D017374	none
paroxetine	9-hydroxyrisperidone	6	6	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		32937	none	D017374	none
paroxetine	9-hydroxyrisperidone	7	6	false	none	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  		32937	none	D017374	none
paroxetine	9-hydroxyrisperidone	7	6	false	none	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  		32937	none	D017374	none
paroxetine	9-hydroxyrisperidone	8	6	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  		32937	none	D017374	none
paroxetine	9-hydroxyrisperidone	8	6	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  		32937	none	D017374	none
paroxetine	atomoxetine	5	7	true	positive	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  		32937	none	D017374	none
paroxetine	atomoxetine	5	7	true	positive	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  		32937	none	D017374	none
paroxetine	atomoxetine	6	7	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  		32937	none	D017374	none
paroxetine	atomoxetine	6	7	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  		32937	none	D017374	none
paroxetine	atomoxetine	6	8	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  		32937	none	D017374	none
paroxetine	atomoxetine	6	8	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  		32937	none	D017374	none
paroxetine	atomoxetine	7	7	true	negative	The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  		32937	none	D017374	none
paroxetine	atomoxetine	7	7	true	negative	The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  		32937	none	D017374	none
paroxetine	atomoxetine	7	8	true	negative	The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  		32937	none	D017374	none
paroxetine	atomoxetine	7	8	true	negative	The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  		32937	none	D017374	none
paroxetine	atomoxetine	7	9	true	positive	The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone.  		32937	none	D017374	none
paroxetine	atomoxetine	7	9	true	positive	The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone.  		32937	none	D017374	none
paroxetine	atomoxetine	8	7	true	negative	The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  		32937	none	D017374	none
paroxetine	atomoxetine	8	7	true	negative	The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  		32937	none	D017374	none
paroxetine	atomoxetine	8	8	true	positive	In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  		32937	none	D017374	none
paroxetine	atomoxetine	8	8	true	positive	In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  		32937	none	D017374	none
paroxetine	atomoxetine	8	9	true	positive	In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone.  		32937	none	D017374	none
paroxetine	atomoxetine	8	9	true	positive	In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone.  		32937	none	D017374	none
paroxetine	atomoxetine	8	10	true	positive	In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone.  Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when given with paroxetine.  		32937	none	D017374	none
paroxetine	atomoxetine	8	10	true	positive	In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone.  Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when given with paroxetine.  		32937	none	D017374	none
paroxetine	atomoxetine	10	8	true	positive	In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone.  Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when given with paroxetine.  		32937	none	D017374	none
paroxetine	atomoxetine	10	8	true	positive	In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone.  Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when given with paroxetine.  		32937	none	D017374	none
paroxetine	atomoxetine	10	9	true	positive	This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone.  Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when given with paroxetine.  		32937	none	D017374	none
paroxetine	atomoxetine	10	9	true	positive	This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone.  Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when given with paroxetine.  		32937	none	D017374	none
paroxetine	atomoxetine	10	10	true	positive	Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when given with paroxetine.  		32937	none	D017374	none
paroxetine	atomoxetine	10	10	true	positive	Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when given with paroxetine.  		32937	none	D017374	none
paroxetine	risperidone	3	5	true	positive	In most patients (>90%), this CYP2D6 isozyme is saturated early during paroxetine dosing.  In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  		32937	none	D017374	none
paroxetine	risperidone	3	5	true	positive	In most patients (>90%), this CYP2D6 isozyme is saturated early during paroxetine dosing.  In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  		32937	none	D017374	none
paroxetine	risperidone	4	5	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  		32937	none	D017374	none
paroxetine	risperidone	4	5	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  		32937	none	D017374	none
paroxetine	risperidone	4	6	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		32937	none	D017374	none
paroxetine	risperidone	4	6	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		32937	none	D017374	none
paroxetine	risperidone	5	5	false	none	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  		32937	none	D017374	none
paroxetine	risperidone	5	5	false	none	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  		32937	none	D017374	none
paroxetine	risperidone	5	6	true	positive	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		32937	none	D017374	none
paroxetine	risperidone	5	6	true	positive	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		32937	none	D017374	none
paroxetine	risperidone	6	5	true	positive	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		32937	none	D017374	none
paroxetine	risperidone	6	5	true	positive	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		32937	none	D017374	none
paroxetine	risperidone	6	6	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		32937	none	D017374	none
paroxetine	risperidone	6	6	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		32937	none	D017374	none
paroxetine	risperidone	7	5	true	positive	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  		32937	none	D017374	none
paroxetine	risperidone	7	5	true	positive	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  		32937	none	D017374	none
paroxetine	risperidone	7	6	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  		32937	none	D017374	none
paroxetine	risperidone	7	6	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  		32937	none	D017374	none
paroxetine	risperidone	8	6	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  		32937	none	D017374	none
paroxetine	risperidone	8	6	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  		32937	none	D017374	none
paroxetine	desipramine	2	4	true	positive	Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme.  In most patients (>90%), this CYP2D6 isozyme is saturated early during paroxetine dosing.  In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  		32937	3247	D017374	3247
paroxetine	desipramine	2	4	true	positive	Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme.  In most patients (>90%), this CYP2D6 isozyme is saturated early during paroxetine dosing.  In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  		32937	3247	D017374	3247
paroxetine	desipramine	3	4	true	positive	In most patients (>90%), this CYP2D6 isozyme is saturated early during paroxetine dosing.  In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  		32937	3247	D017374	3247
paroxetine	desipramine	3	4	true	positive	In most patients (>90%), this CYP2D6 isozyme is saturated early during paroxetine dosing.  In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  		32937	3247	D017374	3247
paroxetine	desipramine	4	4	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  		32937	3247	D017374	3247
paroxetine	desipramine	4	4	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  		32937	3247	D017374	3247
paroxetine	desipramine	5	4	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  		32937	3247	D017374	3247
paroxetine	desipramine	5	4	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  		32937	3247	D017374	3247
paroxetine	desipramine	6	4	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		32937	3247	D017374	3247
paroxetine	desipramine	6	4	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		32937	3247	D017374	3247
paroxetine	p450	1	1	false	none	Many drugs, including most drugs effective in the treatment of major depressive disorder (paroxetine, other SSRIs, and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6.  		32937	none	D017374	none
paroxetine	p450	1	1	false	none	Many drugs, including most drugs effective in the treatment of major depressive disorder (paroxetine, other SSRIs, and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6.  		32937	none	D017374	none
paroxetine	p450	2	1	false	none	Many drugs, including most drugs effective in the treatment of major depressive disorder (paroxetine, other SSRIs, and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6.  Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme.  		32937	none	D017374	none
paroxetine	p450	2	1	false	none	Many drugs, including most drugs effective in the treatment of major depressive disorder (paroxetine, other SSRIs, and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6.  Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme.  		32937	none	D017374	none
paroxetine	p450	3	1	false	none	Many drugs, including most drugs effective in the treatment of major depressive disorder (paroxetine, other SSRIs, and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6.  Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme.  In most patients (>90%), this CYP2D6 isozyme is saturated early during paroxetine dosing.  		32937	none	D017374	none
paroxetine	p450	3	1	false	none	Many drugs, including most drugs effective in the treatment of major depressive disorder (paroxetine, other SSRIs, and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6.  Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme.  In most patients (>90%), this CYP2D6 isozyme is saturated early during paroxetine dosing.  		32937	none	D017374	none
9-hydroxyrisperidone	atomoxetine	6	7	false	none	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  		none	none	none	none
9-hydroxyrisperidone	atomoxetine	6	8	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  		none	none	none	none
9-hydroxyrisperidone	risperidone	6	5	true	positive	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		none	none	none	none
9-hydroxyrisperidone	risperidone	6	6	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		none	none	none	none
9-hydroxyrisperidone	desipramine	6	4	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		none	3247	none	3247
9-hydroxyrisperidone	desipramine	6	4	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		none	3247	none	3247
atomoxetine	risperidone	7	5	false	none	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  		none	none	none	none
atomoxetine	risperidone	7	6	false	none	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  		none	none	none	none
atomoxetine	risperidone	8	6	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.  In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.  		none	none	none	none
risperidone	desipramine	5	4	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  		none	3247	none	3247
risperidone	desipramine	5	4	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  		none	3247	none	3247
risperidone	desipramine	6	4	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		none	3247	none	3247
risperidone	desipramine	6	4	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  		none	3247	none	3247
